Navigation Links
Debiopharm Group Announces Completion of Recruitment for Phase III Clinical Study with Triptorelin 22.5 mg in Central Precocious Puberty
Date:1/13/2014

LAUSANNE, Switzerland, January 13, 2014 /PRNewswire/ --

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, announces that it has completed the recruitment of patients for its Phase III clinical study in Central Precocious Puberty (CPP) with triptorelin 22.5 mg.

Debiopharm is investigating the efficacy and safety of the gonadotropin releasing hormone (GnRH) agonist analog triptorelin pamoate 6-month formulation in the treatment of children suffering from central (GnRH-dependent) precocious puberty (CPP). CPP is defined by pubertal development occurring before the age of 8 years in girls and 9 years in boys, which is not secondary to exposure to sex steroids of adrenal or gonadal origin (peripheral precocious puberty). This 6-month formulation offers an excellent treatment option in a pediatric indication due to less frequent injections. No GnRH agonist 6-month formulation is currently approved for treatment of precocious puberty. The study is an international, multicenter, non-controlled phase III study on the efficacy, pharmacokinetics and safety of two consecutive intramuscular injections of the triptorelin pamoate 22.5 mg 6-month formulation over 12 months. The protocol has gone through the US Food and Drug Administration (FDA) Special Protocol Assessment procedure. The recruitment has been completed and the results are expected in Q4 2014.

"We are very happy to have completed the recruitment in this study," said Eija Lundström, Medical Director responsible for this project at Debiopharm International. "We are looking forward to the results at the end of this year as we believe that the 6-month formulation will simplify the treatment of CPP and make it more tolerable for this young population of patients."


'/>"/>

SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Debiopharm Group and TCG Lifesciences Ltd. Enter into an Exclusive Research Agreement to Develop a Novel Class of Antibiotics, a New Strategic Therapeutic Area for Debiopharm
2. Go To Market Consulting Inc. and Debiopharm Group Collaborate to Identify Early Stage In-licensing Opportunities on the US West Coast
3. Quartz Bio SA Supports Debiopharm Group Precision Medicine Bioinformatics
4. Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers
5. Debiopharm Group to Support Ascepion in the Development of Debio 1144 for the Treatment of Chinese Cancer Patients
6. The Japanese Cancer Association and Debiopharm Group Present Doctors Oshima and Tanaka with the 2012 JCA-Mauvernay Award for their Innovative and Outstanding Cancer Research
7. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
8. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
9. Practice Fusion Partners with Healthagens Practice iQ to Help Physician Groups Perform as ACOs
10. Chris Kilbee Appointed Group Director of UBM Pharma Portfolio
11. FDA Warns of Health Complications from Transvaginal Mesh Erosion, Says Life Care Solutions Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes ... investigational drug for cancer, is designed for injection into ... Its oncology focus is on melanoma, breast cancer and ... trials of PV-10 as a therapy for metastatic melanoma, ... dermatitis and psoriasis. This summer, the ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)... California , 20 de octubre de 2014 ... en el campo de la pulmonología intervencional, anunció ... Estudio RENEW, casi 3 meses antes de lo ... de exención de dispositivo de investigación (IDE) aprobada ... para el sistema de espiral de reducción de ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... 2 Data presented today,at the Annual Congress ... investigational oral Factor Xa inhibitor DU-176b reduced the ... patients,undergoing elective unilateral hip replacement surgery. There was ... and the,observed bleeding rates were low across the ...
... Stenting Safe and Effective in Patients ... Has Been Open-Heart Surgery, WASHINGTON, Sept. 1 ... patients with very complex coronary,artery disease can safely choose ... open-heart surgery, says The Society for,Cardiovascular Angiography and Interventions ...
Cached Medicine Technology:Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b 2SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 2SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 3
(Date:10/22/2014)... Shriners Hospitals for Children® and UK ... current location of Shriners Hospitals for Children - Lexington ... the University of Kentucky Albert B. Chandler Hospital. The ... owned and operated by Shriners Hospitals for Children, and ... and their families well into the future. , “The ...
(Date:10/22/2014)... OR (PRWEB) October 22, 2014 During ... California’s fresh water supply runs dangerously low, Southern Oregon’s ... Southern Oregon’s rivers, despite the lowest mountain snow pack ... in late summer and early autumn.* That was the ... of the new book “Hiking Southern Oregon,” during an ...
(Date:10/22/2014)... Although there are only 24 hours in a day, that doesn’t ... finding time within their busy schedules for exercise and fitness. Fortunately, ... to get in shape. Here are five ways you can reach ... Change Up Your Commute , Consider riding a bike or taking ... your daily routine. If you must use your car to get ...
(Date:10/22/2014)... By Steven Reinberg ... -- Infants who quickly add weight and length may be ... study suggests. In adults, certain genes have been linked ... promote proportionate gains in fat and lean muscle, the researchers ... be heavier and taller. By ages 2 and 3, however, ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... especially common after the death of a spouse , , ... keep up active social lives as they age may ... finds. , Being socially active may increase feelings ... helping maintain memory, researchers say. Social interaction may also ...
... May 29 PartnerRe Ltd.,(NYSE: PRE ) today ... Benchimol is scheduled to present at the Fox,Pitt-Kelton Cochran ... Opportunities for the Insurers... and the Contrast with,Banks." The ... 6, 2008 from 9 a.m. - 2 p.m. local ...
... published a,new report designed to provide critical strategic ... in the market for diagnostics and treatments,in this ... &,Analysis: Alzheimer,s Disease," is based on in-depth interviews ... involved in ongoing,research., "There is some real ...
... New three-year agreement extends alliance members, access to medical product ... ... systems., LOUDON, Tenn., May 29 Adroit ... by Premier,Purchasing Partners, LP. The new agreement centers on Adroit,s leading,Soft-Temp(R) ...
... Help Firms That Already Offer Insurance to Workers, ERIE, ... than 10,000 uninsured adults in Erie County -- many of ... are on a waiting list,to receive health care coverage -- ... them gain access to health insurance., He said small ...
... DR ),is excited to announce the creation ... division and the errors and omissions (E&O),division., ... leadership of senior vice president and national practice,leader, ... combines all,of Darwin,s health care-related professional liability teams ...
Cached Medicine News:Health News:Active Social Life Helps Keep Aging Mind Sharp 2Health News:Active Social Life Helps Keep Aging Mind Sharp 3Health News:PartnerRe Executive Vice President & Chief Financial Officer Albert Benchimol to Present at the FPK CCW Credit Risk Conference in London on June 6, 2008 2Health News:Cardiovascular Meds May Be Beneficial in Alzheimer's Disease, According to MedPredict Report 2Health News:Adroit Medical Systems Awarded Premier Supplier Contract for Temperature Therapy Systems 2Health News:Governor Rendell Says PA ABC Will Help Low-Wage Small Businesses Pay for Employee Health Coverage 2Health News:Governor Rendell Says PA ABC Will Help Low-Wage Small Businesses Pay for Employee Health Coverage 3Health News:Governor Rendell Says PA ABC Will Help Low-Wage Small Businesses Pay for Employee Health Coverage 4Health News:Darwin Announces Creation of New Health Care and Errors and Omissions Divisions 2Health News:Darwin Announces Creation of New Health Care and Errors and Omissions Divisions 3
... Stealthstation Siremobil Iso-C3D C-Arm imaging system interface ... of mobile C-arm imaging. Combining mobility ... software, the cooperative technologies deliver the most ... 3D imaging is the new standard in ...
... The best of digital mobile imaging ... of,anatomical localization software and instrumentation. Now ... capability to:, Easily Add Visualization ... Dose, Accelerate Intraoperative Decision Making, ...
... the most advanced imaging capabilities into the ... it offers many of the same technologies ... value-oriented platform. Asteion provides the subsecond speed ... scanning, while also supporting everyday, high-resolution scanning ...
... the T.L.I.F. SG Instruments are the ... surgery, offering comprehensive and functionally sound instruments.. ... variety of disc removal and disc preparation ... TLIF procedure. Excellent design, a wide range ...
Medicine Products: